Physician profile
Brent William Acker
NPI 1407147028
$9,621.83
in general payments reported to CMS, 2019-2025
39 companies · $1,765 in 2025
The $1,765 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $550 · 2021: $1,140 · 2022: $1,587 · 2023: $1,940 · 2024: $1,719 · 2025: $1,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,424.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,036.93 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,589.33 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $909.25 | 2019-2025 | Stelara, Tremfya, Remicade |
| Gilead Sciences, INC. | $588.36 | 2019-2025 | Vemlidy |
| Takeda Pharmaceuticals U.S.A., INC. | $453.12 | 2019-2025 | Entyvio, Gattex |
| Merck Sharp & Dohme LLC | $332.41 | 2019-2024 | Dificid |
| Genzyme Corporation | $249.15 | 2023-2025 | |
| Madrigal Pharmaceuticals | $228.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $203.28 | 2019-2022 | |
| Pfizer INC. | $165.11 | 2019-2025 | |
| Redhill Biopharma INC. | $158.58 | 2020-2022 | |
| Boston Scientific Corporation | $153.78 | 2021-2025 | Resolution 360 Clip, Watchman Flx, General - Hemostasis |
| Qol Medical, LLC | $132.60 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $131.86 | 2023-2025 | Ibsrela |
| Celgene Corporation | $117.26 | 2021-2024 | Zeposia |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Acker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.